GMP Certified Heparin Sodium Injection 5000iu/5ml Support OEM

• Application: Internal Medicine
• Usage Mode: for Injection
• Suitable for: Elderly, Children, Adult
• State: Liquid
• Shape: for Injection
• Type: Organic Chemicals
• Model NO.: AMC14085
• Pharmaceutical Technology: Chemical Synthesis
• Certification: GMP
• Delivery Time: 45-60 Days
• Support: OEM,ODM
• Standard: Bp,Cp,USP
• Transport Package: 24X0.5ml
• Specification: 5000IU/5ML
• Trademark: Shinepharm
• Origin: China
• HS Code: 3004909099
• Production Capacity: 1000000 Boxes/Month

Product Description

HYOSCINE BUTYLBROMIDE INJECTION 10MG/1ML

Indicatios:

Hyoscine butylbromide is indicated in acute spasm, as in renal or biliary colic, in radiology for differential diagnosis of obstruction and to reduce spasm and pain in pyelography, and in other diagnostic procedures where spasm may be a problem (e.g. gastroduodenal endoscopy).

Dosage and administration:

Adults

20 mg intravenously or intramuscularly, repeated after half an hour if necessary. Intravenous injection should be performed 'slowly' (in rare cases a marked drop in blood pressure and even shock may be produced by hyoscine injection).

When used in endoscopy this dose may need to be repeated more frequently.

Maximum daily dose is 100 mg.

Special populations

Paediatric population

Not recommended.

Hyoscine butylbromide injection should not be used on a continuous daily basis or for extended periods without investigating the cause of abdominal pain.

Method of administration

For intravenous and intramuscular injection.

Hyoscine butylbromide solution for injection may be used diluted with glucose or with sodium chloride 0.9% solution for injection.

Contraindications:

Hyoscine butylbromide is contraindicated in patients with:

- hypersensitivity to the active substance or to any of the excipients

- narrow angle glaucoma

- prostate hypertrophy with urinary retention

- mechanical stenosis in the gastrointestinal tract

- paralytic or obstructive ileus

- megacolon

- tachycardia

- myasthenia gravis

Hyoscine butylbromide should not be given by intramuscular injection to patients being treated with anticoagulant drugs since intramuscular haematoma may occur.

Precautions:

In case severe, unexplained abdominal pain persists or worsens, or occurs together with symptoms like fever, nausea, vomiting, changes in bowel movements, abdominal tenderness, decreased blood pressure, fainting, or blood in stool, appropriate diagnostic measures are needed to investigate the aetiology of the symptoms.

Hyoscine butylbromide can cause tachycardia, hypotension and anaphylaxis, therefore use with caution in patients with cardiac conditions such as cardiac failure, coronary heart disease, cardiac arrhythmia or hypertension, and in cardiac surgery. Monitoring of these patients is advised. Emergency equipment and personnel trained in its use must be readily available.

Because of the possibility that anticholinergics may reduce sweating, hyoscine butylbromide should be administered with caution to patients with pyrexia.

Elevation of intraocular pressure may be produced by the administration of anticholinergic agents such as hyoscine butylbromide in patients with undiagnosed and therefore untreated narrow angle glaucoma. Therefore, patients should seek urgent ophthalmological advice in case they should develop a painful, red eye with loss of vision after the injection of hyoscine butylbromide.

After parenteral administration of hyoscine butylbromide, cases of anaphylaxis including episodes of shock have been observed. As with all drugs causing such reactions, patients receiving hyoscine butylbromide should be kept under observation.

Drug interactions:

The anticholinergic effect of drugs such as tri- and tetracyclic antidepressants, antihistamines, antipsychotics (e.g. phenothiazines,butyrophenones), quinidine, disopyramide, amantadine, and other anticholinergics (e.g. tiotropium, ipratropium, atropine-like compounds) may be intensified by hyoscine butylbromide.

The tachycardic effects of beta-adrenergic agents may be enhanced by hyoscine butylbromide.

Concomitant treatment with dopamine antagonists such as metoclopramide may result in diminution of the effects of both drugs on the gastrointestinal tract.

Storage:

Store at or below 30°C protected from light. For single use only. Once opened, any unused portion should be discarded.

Hyoscine Butylbromide Injection Other Specifications:

Heparin Sodium Injection 5000iu/5ml

Ingredient Broadcast
The main ingredient of this product is heparin sodium.

Trasit Broadcast
This product is colorless to light yellow clear liquid.

Indication Broadcast
For the prevention and treatment of thrombosis or embolism diseases (such as myocardial infarction, thrombophlebitis, pulmonary embolism, etc.); disseminated intravascular coagulation (DIC) caused by various reasons; also used for hemodialysis, extracorporeal circulation, catheterization, Anticoagulation treatment of certain blood samples or instruments in operations such as microvascular surgery.

Specifications Broadcast
2ml: 12,500 units

Usage and Dosage
1. Deep subcutaneous injection: 5,000-10,000 units for the first time, 8,000-10,000 units every 8 hours or 15,000-20,000 units every 12 hours; the total amount is about 30,000-40,000 units every 24 hours, and generally can achieve satisfactory results.
2. Intravenous injection: After the first 5,000-10,000 units, or 100 units/kg every 4 hours according to body weight, dilute with sodium chloride injection and apply.
3. Intravenous infusion: Add 20,000 to 40,000 units per day to 1,000ml of sodium chloride injection for continuous infusion. Intravenous injection of 5000 units can be used as the initial dose before instillation.
4. Preventive treatment: For patients with high-risk thrombosis, it is mostly used after abdominal surgery to prevent deep vein thrombosis. Give 5000 units of heparin subcutaneously 2 hours before the operation, but epidural anesthesia should be avoided in the way of anesthesia, and then 5000 units every 8 to 12 hours for a total of about 7 days.

Adverse Reaction Broadcast
The toxicity is low, and the main adverse reaction is that excessive medication can cause spontaneous bleeding, so the coagulation time should be measured before each injection. If severe bleeding is caused after the injection, protamine sulfate can be injected intravenously for first aid (1mg protamine sulfate can neutralize 100U heparin).
Occasionally, it can cause allergic reactions and thrombocytopenia often occurs in the first 5 to 9 days of medication, so the platelet count should be monitored regularly within 1 month after starting treatment. Occasionally one-time hair loss and diarrhea. Can still cause osteoporosis and spontaneous fractures. Long-term use in patients with poor liver function can cause depletion of antithrombin- and thrombosis tendency.

Taboo Broadcast
Those who are allergic to heparin, those with spontaneous bleeding tendency, those with slow blood coagulation (such as hemophilia, purpura, thrombocytopenia), ulcer disease, trauma, postpartum hemorrhage and severe liver insufficiency are contraindicated.

Precaution Broadcast
The coagulation time should be measured regularly during the medication.
Medication for pregnant and breastfeeding women
Late pregnancy and postpartum medication may increase the risk of maternal hemorrhage and should be used with caution.

Medication for Children
1. Intravenous injection: Inject 50 units of 1 kg at a time according to body weight, and then give 50-100 units every 4 hours;
2. Intravenous infusion: Inject 50 units/kg according to body weight, then give 20,000 units/m2 per day according to body surface area for 24 hours, add sodium chloride injection and instill slowly.

Medication for the Elderly
Elderly people over 60 years old, especially elderly women are more sensitive to this drug and are prone to bleeding during medication, so the dosage should be reduced and follow-up should be strengthened.

Drug Interaction Broadcast
Combination of this product with the following drugs can increase the risk of bleeding:
1. Coumarin and its derivatives can cause severe factor IX deficiency and cause bleeding;
2. Aspirin and non-steroidal anti-inflammatory analgesics, including mefenamic acid and salicylic acid, can inhibit platelet function and induce gastrointestinal ulcer bleeding;
3. Dipyridamole, dextran, etc. may inhibit platelet function;
4. Adrenal corticosteroids, corticotropic hormones, etc. can easily induce gastrointestinal ulcer bleeding;
5. Others include diuretic acid, tissue plasminogen activator (t-PA), urokinase, streptokinase, etc.
6. For heparin, drugs such as sodium bicarbonate and sodium lactate to correct acidosis can promote the anticoagulant effect of heparin.
7. The mixed injection of heparin and hyaluronidase can not only reduce the pain of intramuscular injection, but also promote the absorption of heparin. However, heparin can inhibit the activity of hyaluronidase, so the two should be used in combination temporarily, and the drugs should not be stored for a long time after mixing.
8. Heparin can interact with  receptors, thereby changing the binding and action of. There have been reports of hypoglycemia caused by the liver.
9. The following drugs have incompatibility with this product: kanamycin, amikacin, daunorubicin, erythromycin lactobionate, gentamicin sulfate, h sodium succinate, polymyxin B. Adriamycin, tobramycin, vancomycin, cefamandole, cefoperazole, cefalotin sodium, chloroquine, chlorpromazine, promethazine, narcotic analgesics.
10. Methimazole, propylthiouracil and this product have a synergistic effect.

More Specifications

AMC14085-01	HEPARIN SODIUM INJECTION	5000IU/ML,1'S/BOX,
AMC14085-02	HEPARIN SODIUM INJECTION	12500IU/2ML,1'S/BOX
AMC14085-03	HEPARIN SODIUM INJECTION	5000IU/5ML,1'S/BOX
AMC14085-04	HEPARIN SODIUM INJECTION	25000IU/5ML,1'S/BOX
AMC14085-05	HEPARIN SODIUM INJECTION	1000IU/ML,1'S/BOX
AMC14085-06	HEPARIN SODIUM INJECTION	1000IU/ML,5ML,5'S/BOX
AMC14085-07	HEPARIN SODIUM INJECTION	5000IU/2ML,5'S/BOX
AMC14085-08	HEPARIN SODIUM INJECTION	1000IU/ML,10'S/BOX
AMC14085-09	HEPARIN SODIUM INJECTION	2000IU/2ML,10'S/BOX
AMC14085-10	HEPARIN SODIUM INJECTION	5000IU/5ML,10'S/BOX
AMC14085-11	HEPARIN SODIUM INJECTION	2500IU/2ML,25'S/BOX
AMC14085-12	HEPARIN SODIUM INJECTION	25000IU/5ML,10'S/BOX

 

 

More Products:

 

More Products: